Leucine-Rich Diet Improved Muscle Function in Cachectic Walker 256 Tumour-Bearing Wistar Rats.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI
    • Subject Terms:
    • Abstract:
      Skeletal muscle atrophy occurs in several pathological conditions, such as cancer, especially during cancer-induced cachexia. This condition is associated with increased morbidity and poor treatment response, decreased quality of life, and increased mortality in cancer patients. A leucine-rich diet could be used as a coadjutant therapy to prevent muscle atrophy in patients suffering from cancer cachexia. Besides muscle atrophy, muscle function loss is even more important to patient quality of life. Therefore, this study aimed to investigate the potential beneficial effects of leucine supplementation on whole-body functional/movement properties, as well as some markers of muscle breakdown and inflammatory status. Adult Wistar rats were randomly distributed into four experimental groups. Two groups were fed with a control diet (18% protein): Control (C) and Walker 256 tumour-bearing (W), and two other groups were fed with a leucine-rich diet (18% protein + 3% leucine): Leucine Control (L) and Leucine Walker 256 tumour-bearing (LW). A functional analysis (walking, behaviour, and strength tests) was performed before and after tumour inoculation. Cachexia parameters such as body weight loss, muscle and fat mass, pro-inflammatory cytokine profile, and molecular and morphological aspects of skeletal muscle were also determined. As expected, Walker 256 tumour growth led to muscle function decline, cachexia manifestation symptoms, muscle fibre cross-section area reduction, and classical muscle protein degradation pathway activation, with upregulation of FoxO1, MuRF-1, and 20S proteins. On the other hand, despite having no effect on the walking test, inflammation status or muscle oxidative capacity, the leucine-rich diet improved muscle strength and behaviour performance, maintained body weight, fat and muscle mass and decreased some protein degradation markers in Walker 256 tumour-bearing rats. Indeed, a leucine-rich diet alone could not completely revert cachexia but could potentially diminish muscle protein degradation, leading to better muscle functional performance in cancer cachexia.
    • References:
      Front Physiol. 2019 Feb 18;10:41. (PMID: 30833900)
      Eur J Clin Nutr. 2014 Nov;68(11):1220-7. (PMID: 25139559)
      FASEB J. 1998 Jul;12(10):871-80. (PMID: 9657527)
      Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E381-7. (PMID: 16507602)
      Nutrients. 2020 May 02;12(5):. (PMID: 32370170)
      Cancers (Basel). 2020 Jul 13;12(7):. (PMID: 32668598)
      BMC Cancer. 2019 Apr 11;19(1):349. (PMID: 30975087)
      Food Funct. 2021 Aug 2;12(15):6712-6724. (PMID: 34160501)
      FASEB J. 2016 Sep;30(9):3053-68. (PMID: 27206451)
      Am J Physiol Endocrinol Metab. 2013 May 15;304(10):E1042-52. (PMID: 23531613)
      Nutrition. 2014 Jul-Aug;30(7-8):807-13. (PMID: 24984997)
      Cytokine. 2013 Feb;61(2):532-9. (PMID: 23200412)
      Am J Clin Nutr. 2016 Feb;103(2):465-73. (PMID: 26718415)
      J Nutr. 2000 Nov;130(11):2630-5. (PMID: 11053498)
      PLoS One. 2014 Jan 08;9(1):e85283. (PMID: 24416379)
      Biochim Biophys Acta. 2013 Mar;1830(3):2770-8. (PMID: 23200745)
      J Nutr. 1993 Nov;123(11):1939-51. (PMID: 8229312)
      Surgery. 1999 Oct;126(4):744-9; discussion 749-50. (PMID: 10520924)
      Exp Gerontol. 2015 Dec;72:269-77. (PMID: 26481769)
      Amino Acids. 2017 Jun;49(6):1005-1028. (PMID: 28324172)
      J Appl Physiol (1985). 2018 Mar 1;124(3):684-695. (PMID: 29122966)
      Braz J Med Biol Res. 2017 Oct 19;50(12):e6733. (PMID: 29069231)
      Sci Rep. 2019 Oct 29;9(1):15529. (PMID: 31664147)
      Domest Anim Endocrinol. 2016 Jul;56 Suppl:S23-32. (PMID: 27345321)
      FASEB J. 2004 Jan;18(1):39-51. (PMID: 14718385)
      BMC Cancer. 2016 Oct 3;16(1):764. (PMID: 27716121)
      Biol Reprod. 2013 May 16;88(5):121. (PMID: 23553429)
      Amino Acids. 2013 Oct;45(4):901-11. (PMID: 23812674)
      J Biol Chem. 1999 Apr 23;274(17):11647-52. (PMID: 10206976)
      Nat Protoc. 2008;3(6):965-76. (PMID: 18536644)
      Br J Cancer. 2006 Oct 23;95(8):1028-37. (PMID: 17047651)
      J Nutr. 2000 Oct;130(10):2413-9. (PMID: 11015466)
      Lipids. 2007 Apr;42(4):297-305. (PMID: 17406924)
      Front Pharmacol. 2017 Apr 05;8:185. (PMID: 28424622)
      Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2500-5. (PMID: 14983038)
      Nutrients. 2014 Apr 02;6(4):1364-73. (PMID: 24699194)
      Nat Rev Cancer. 2014 Nov;14(11):754-62. (PMID: 25291291)
      Curr Opin Support Palliat Care. 2016 Dec;10(4):281-287. (PMID: 27454355)
      Nat Rev Dis Primers. 2018 Jan 18;4:17105. (PMID: 29345251)
      Curr Opin Support Palliat Care. 2008 Dec;2(4):262-6. (PMID: 19069311)
      Oncol Rep. 2011 Jul;26(1):247-54. (PMID: 21503587)
      Front Physiol. 2016 Jan 12;6:422. (PMID: 26793123)
      Nutrients. 2020 Mar 27;12(4):. (PMID: 32230954)
    • Grant Information:
      #2012/06955-0; #2014/13334-7; #2015/21890-0; #2017/02739-4; #2019/14803-4 São Paulo Research Foundation; #302863/2013-3; #302425/2016-9; #301771/2019-7 National Council for Scientific and Technological Development; 001 Coordenação de Aperfeicoamento de Pessoal de Nível Superior
    • Contributed Indexing:
      Keywords: cancer cachexia; leucine supplementation; muscle function; protein degradation
    • Accession Number:
      0 (Forkhead Box Protein O1)
      0 (Muscle Proteins)
      0 (Tripartite Motif Proteins)
      EC 2.3.2.27 (Trim63 protein, rat)
      EC 2.3.2.27 (Ubiquitin-Protein Ligases)
      GMW67QNF9C (Leucine)
    • Publication Date:
      Date Created: 20211224 Date Completed: 20220120 Latest Revision: 20220120
    • Publication Date:
      20231215
    • Accession Number:
      PMC8699792
    • Accession Number:
      10.3390/cells10123272
    • Accession Number:
      34943780